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S160 Oral Presentationsphenotype as determined by FACS staining. The cells produced the
pro-inflammatory cytokines IL1b, IL6, IL17, IP10, IFNg and
TNFa as determined byMultiplex immuno-assay and the cytotoxins
perforin and granzyme B, all necessary for viral elimination.
The generation of HAdV specific T-cells from naive UCB cells in
response to 15-mer HAdV peptides seems an essential step in devel-
oping a more tailor-made adoptive therapy for HAdV infection for
recipients of UCB transplants.
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FLAGELLIN-TLR5 IMMUNE RESPONSE: A NOVEL MECHANISM TO RE-
DUCE GVHD IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
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Background: Immunosuppressive drugs are used to limit GvHD
but causes complications. To develop an alternative approach to
control GvHD, we tested the immunomodulatory immune proper-
ties of flagellin, a bacterial protein that agonistically binds with
TLR5.
Methods: We used established B6 to CB6F1 and B10.BR to B6 allo-
geneicHSCT recipients had both acute and chronicGvHD. 50 mg fla-
gellin administered i.p 3 hours before 11 Gy irradiation. 5 million (M)
T-cell depleted bone marrow (TCDBM) and 5 M splenocytes of con-
geneic donors were transplanted i.v. 24 hours later another dose of fla-
gellin were administered i.p. Control recipients were treated with
0.2 ml PBS i.p. HSCT mice were monitored every day for mortality.
Weight of individual mice was measured twice a week until 30 days
post transplant and once a week after that tomeasureGvHD. Immune
reconstitution was determined by measuring immune cells/organs and
infecting the recipients with 510E3 pfu MCMV i.p.
Results: Flagellin treated recipients of in B6 to F1 model survived
100% and gained weight to almost normal level within 66 days post
transplant.But the control groupsurvived80%andhadsignsof chronic
GvHD. Flagellin-treated recipients in B10 to B6 model had 15%
weight-loss and 33% transplant-related death by 132 days post trans-
plant versus had severe acute GvHD and 100% early post-transplant
mortality amongcontrolHSCTrecipients. Flagellin-treated recipients
in B6 to F1 model showed 100% chimerism with significantly higher
number of donor spleen- and BM-derived CD4+ and CD8 +T cells
per spleen inuntreated recipientscompared tocontrol recipientswithin
66 days post transplant. In the spleen CFSE labeled CD4 +T cells di-
vided faster in flagellin-treated recipients than the control recipients
and decreasing the number of CD4 +CD62L+ T cells within 4 days
post transplant. B6 to F1 recipients were infected with MCMV on
70+dayspost transplant.Controlmicediedwithinday10post infection
whereas flagellin-treated recipients recovered from MCMV infection
and had higher number anti-viral+ CD8 +T cells in their blood on
day 10 and 35 post infection. Increased numbers of
CD25+foxp3 +CD4+ regulatoryT cells were alsomeasured from their
thymus on day 35 post MCMV infection.
Conclusion: Flagellin treatment successfully controlled GvHD, en-
hances donor T-cell engraftment, had brisk and persistent cellular
immune responses in lymphoid organs to protect recipients from vi-
ral infection.16
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Background: Incidence and risk factors for post-transplant diabetes
mellitus (PTDM) and long-term development of metabolic syn-drome (MS) after allogeneic stem cell transplantation (allo-SCT)
are not well defined.We conducted a prospective study of 84 patients
(pts) undergoing allo-SCT with cyclosporine-based graft-versus-
host disease (GVHD) prophylaxis to evaluate risk factors and inci-
dence of PTDM in the first 100 days. Prevalence of MS at long-
term followup was assessed.
Methods: Allo-SCT candidates without preexisting DM who met
screening criteria were enrolled. Demographic data and baseline
laboratory data including fasting blood glucose (FBG), lipids, insu-
lin, c-peptide, and fructosamine were collected. PTDM was de-
fined by FBG. 126 mg/dl or random BG. 200. Peak dose and
duration of systemic steroid (SS) treatment for GVHD was col-
lected. MS was defined by NCEP ATPIII criteria based on annual
screens.
Results:Median age of pts was 46 years (yrs) (range 21-66). 44 (52%)
were male. Median FBG pre-SCT was 97 (range 79-121). 50 of 84
(60%) pts developed DM at median of 23 days (interquartile range
14.2-33.8) post-transplant. 33 pts completed study to day 100 with-
out PTDM and 1 died before day 100 without PTDM. Age was sim-
ilar regardless of PTDM development. 28 pts (56%) with PTDM
and 16 pts (47%) without PTDMwere exposed to SS prior to reach-
ing endpoints of PTDM or day 100. Pre-transplant c-peptide levels
were higher in pts with PTDM (median 4.45 mg/dL vs 2.55,
p5 0.015). Among pts receiving SS before day 100, pts with
PTDM were more likely to have received. 1 mg/kg/day of SS
(p5 0.002). Median post-transplant followup was 1.5 yrs (range 18
days-3.6 yrs). 45 pts (54%) were screened for MS at their annual
or subsequent visits (17 pts deceased prior to 1 yr post-SCT). Of
the pts for whom long-term metabolic data were collected, 17
(38%) met criteria for MS. Compared to pts who did not develop
MS, these pts were older (56 vs 41.5 yrs, p5 0.005) and had higher
pre-transplant fasting triglyceride levels (177 vs 108 mg/dl,
p5 0.005). Interestingly, GVHD and use of SS were not associated
with development of MS.
Conclusions: Our data suggest that pre-SCT c-peptide predicts
PTDM, while high triglyceride levels and older age associate with
long-termMS.These findingsmay helpwith counseling,monitoring,
and planning interventions to reduce metabolic sequelae after allo-
SCT, which contribute to cardiac complications in young patients af-
ter allo-SCT.17
AUGMENTATION OF HEMATOPOIETIC ENGRAFTMENT WITHOUT GRAFT
VERSUS HOST DISEASE BY ‘‘ADD-BACK’’ OF PHOTOCHEMICALLY
TREATED T LYMPHOCYTES IN MISMATCHED CORD BLOOD TRANSPLAN-
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Introduction: Unrelated cord blood transplantation (CBT) is asso-
ciated with a risk of graft rejection due in part to a limiting cellular
content of the CB unit.We have investigated the co-infusion of pho-
tochemically (psoralen S59) treated mature donor T lymphocytes in
a major histocompatibility complex (MHC) [H2-haplotype] mis-
matched murine transplant model as a new method to facilitate en-
graftment of donor CB cells.
Methods: We analyzed the rates of donor hematopoietic cell en-
graftment, graft versus host disease (GVHD), and long-term survival
in H2 haplotype disparate [C57BL/6 (H2Kk/Thy1.1)/AKR
(H2Kb/Thy1.2)] mice after CBT. Three different experimental
groups were transplanted after sublethal radiation. Group 1 received
allogeneic full term newborn peripheral blood alone, group 2 was
transplanted with the same donor cells and unmanipulated donor
T cells, and group 3 was transplanted with the similar donor cells
and psoralen (S-59) treated donor T cells.
Results:We observed a low rate of donor engraftment after trans-
plantation with cord blood alone (Group 1). The best results were
observed after transplantation with 3 x 106 nucleated cord blood
cells and 9 x106 S-59 treated T cells (Group 3b)(p5 0.007).
The engraftment rate was 75% compared to 12.5% after trans-
plantation with 6 x 106 CB cells alone (p5 0.04). The long-
term survival in group 3 was 100% and the rate and severity of
